Sansure Biotech Inc. (SHA:688289)

Market Cap	11.09B -2.0%
Revenue (ttm)	1.67B +18.7%
Net Income	271.49M +4.7%
EPS	0.40 -8.3%
Shares Out	574.18M
PE Ratio	47.92
Forward PE	35.76
Dividend	0.54 (2.78%)
Ex-Dividend Date	Sep 23, 2025

Volume	3,732,370
Average Volume	10,878,234
Open	19.45
Previous Close	19.54
Day's Range	19.31 - 19.65
52-Week Range	17.73 - 26.36
Beta	0.77
RSI	39.79
Earnings Date	Apr 30, 2026

About Sansure Biotech

Sansure Biotech Inc. researches and develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. It offers nucleic acid and multiple nucleic acid diagnostic kits for coronavirus, CoV-2, influenza virus, and respiratory syncytial virus; DNA fluorescence and nucleic acid diagnostic kits for respiratory tract infections, HPV infections, and reproductive tract infections; nucleic acid tests and fluorescence diagnostic kits for blood-borne infections; RNA diagnostic kits for gastrointestinal infections; an...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 2008
• Employees: 2,409
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688289

Financial Performance

In 2024, Sansure Biotech's revenue was 1.46 billion, an increase of 44.78% compared to the previous year's 1.01 billion. Earnings were 275.60 million, a decrease of -24.23%.